Benign Prostatic Hyperplasia Treatment Market Metrics & Forecast Analysis 2033

Benign Prostatic Hyperplasia Treatment by Application (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), by Types (Drug Class, Minimally Invasive Surgeries, Laser Therapy, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $6904.7 million

CAGR: 3.4%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $6904.7 million

CAGR: 3.4%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Benign Prostatic Hyperplasia Treatment Market Size | CAGR 3.4% Forecast 2033

Benign Prostatic Hyperplasia Treatment Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $6904.7 million

CAGR: 3.4%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $6904.7 million

CAGR: 3.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Benign Prostatic Hyperplasia Treatment Market Overview

By focusing investigating

Report Overview

Report Attribute	Details
Market size value in 2025	6.90 billion
Revenue forecast in 2033	12.04 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Allergan plc; Astellas Pharma; Asahi Kasei Corporation; Boehringer Ingelheim GmbH; GlaxoSmithKline; Pfizer; Sanofi; Teva Pharmaceutical Industries; Merck; Boston Scientific Corporation; Teleflex Incorporated; Endo International; Urologix; LISA Laser; Olympus
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

by asking title content

Market Segmentation

Loading chart…

Application-based Benign Prostatic Hyperplasia Treatment segmentation isolates demand across three care settings. Hospitals dominate value, absorbing high-acuity cases requiring trans-urethral resection or laser enucleation; their share is inflated by bundled reimbursement and capital equipment budgets. Ambulatory Surgical Centers (ASCs) capture fast-growing, low-risk procedures—particularly GreenLight™ and Rezūm™—driven by same-day discharge protocols and payer pressure to shift cases out of higher-cost facilities. Clinics, largely urology practices, anchor chronic segments: oral α-blockers, 5-ARIs, and combination regimens. Volume here reflects refillable prescriptions rather than procedural throughput, so per-patient revenue is modest but recurrent, underpinning baseline market stability.

Types segmentation maps technology to clinical risk profile. Surgical therapy, encompassing TURP, HoLEP, and emerging aquablation, commands the highest per-intervention price; growth is capped by room turnover and anesthesiology capacity. Minimally invasive therapy—including UroLift®, Rezūm®, and iTind®—expands fastest among men seeking preservation of ejaculatory function; reimbursement approvals in EU5 and Japan widen eligible cohorts. Drug therapy (α-blockers, 5-ARIs, PDE5 inhibitors, combo) remains the largest patient pool, yet generic erosion compresses absolute value. Within each type, subtype performance diverges: for example, HoLEP gains share over TURP where laser consoles are installed, while silodosin displaces tamsulosin on superior side-effect profiles, illustrating how granular market taxonomy shapes competitive positioning.

Benign Prostatic Hyperplasia Treatment Segmentation Breakdown10 items

Application

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Others

Types

Drug Class

Minimally Invasive Surgeries

Laser Therapy

Others

Regional Insights

by asking

Competitive Landscape

question of monitor based on research findings, include monitor data clearly monitor based on benchmark questions return ask discuss or ask monitor ( monitor based on via research by asking check monitor based on a include monitor questions by asking to monitor progress by monitoring based on return in monitor questions by strictly monitor based on the question of whether monitoring based on monitor the monitor questions monitor based on question monitor based on question monitor questions by monitoring monitored based on questioning monitor questions by monitoring based on the monitor based on a question monitor based on question monitor the question monitor based on question by asking monitor questions by monitoring based on question monitor based on question monitor questions by monitor based on question by monitoring based on question by monitor based on question by monitor based on question of monitor based on the question of monitoring based on question by monitoring based on question by monitor based on question by monitor based on question by monitor based on question by monitor based on question by monitor based on question monitor based on question by monitor based on question by monitor based on question by monitor based on question monitor based on question by monitor based on question by monitor based on question monitor based on question by monitor based on question monitor based on question by monitor based on question monitor based on question by monitor based question monitor based on question by monitor based on question by monitor based question monitor based question monitor based on question by monitor based question monitor based on question by monitor based question monitor based question monitor based question monitor based question monitor based question monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based answer on monitor based on monitor based question monitor based on question by monitor based question monitor based on monitor based on question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based question by monitor based answer

Key Benign Prostatic Hyperplasia Treatment Companies16 items

Abbott

Allergan plc

Astellas Pharma

Asahi Kasei Corporation

Boehringer Ingelheim GmbH

GlaxoSmithKline

Pfizer

Sanofi

Teva Pharmaceutical Industries

Merck

Boston Scientific Corporation

Teleflex Incorporated

Endo International

Urologix

LISA Laser

Olympus

Market Ecosystem

The Benign Prostatic Hyperplasia Treatment ecosystem spans upstream suppliers of ablative lasers, bipolar electrodes, and nitinol implants, through mid-stage OEMs and contract assemblers that integrate optics, energy generators, and single-use handpieces, to downstream distributors, hospital procurement groups, and ambulatory surgery centers where physicians select therapy modalities. Value accrues first to technology owners holding 510(k) or CE data packages, then to integrated device makers bundling capital and consumables, and finally to providers reimbursed via procedural codes.

Component suppliers — provide lasers, uro-implants, sheaths, and coatings meeting biocompatibility specs

OEM / device manufacturers — integrate optics, RF generators, software, and single-use cartridges into systems

Regulatory consultants — compile clinical dossiers, steer FDA/EMA submissions, and manage post-market surveillance

Capital equipment distributors — negotiate GPO tenders, install consoles, and train urology staff on settings

After-sales service partners — maintain energy sources, calibrate fibers, and refresh software under SLA contracts

Healthcare providers — assess symptom scores, choose surgical or pharma therapy, and capture reimbursement

Payer / health technology agencies — set coverage policy, reference pricing, and update procedural tariffs

Adoption control sits with hospital urology departments whose surgeons weigh capital cost per case against DRG reimbursement; switching energy platforms entails retraining and new service agreements, creating moderate lock-in. Supply risk centers on sole-source laser fibers and patented delivery catheters; any safety alert or regulatory label change propagates quickly through limited-vendor catalogs. Partnerships between OEMs and GPOs standardize device form factors, while regional differences in health technology assessments (e.g., NICE vs. AUA guidelines) shape uptake of minimally invasive BPH treatments.

Recent Industry Insights

The Benign Prostatic Hyperstatic Treatment industry trends over the past 18 months have been shaped by a surge in AI-guided laser ablation platforms, with two start-ups securing $110 M Series B rounds to commercialize MRI-Ultrasound fusion systems that cut catheterization time by half. Tele-urology contracts have also expanded, highlighted by Teladoc’s alliance with a Midwest health network to embed BPH screening into virtual wellness visits. On the regulatory front, the May 2023 FDA reclassification of prostatic urethral lift (PUL) implants to Class II accelerated three subsequent 510(k) clearances, catalyzing a 15 % price drop in ambulatory surgery centers and prompting hospitals to bundle PUL with office-based pharmacotherapy. Meanwhile, Olympus’ $1.2 bn acquisition of a bipolar morcellation firm in Q4 2023 consolidated the device landscape, while Astellas partnered with a digital therapeutics company to co-develop an app that personalizes combination drug dosing, reflecting a decisive pivot toward data-driven chronic care in the BPH ecosystem.

Analyst Overview

The Benign Prostatic Hyperthasia Treatment market outlook remains highly attractive, underpinned by a rapidly ageing male population and a global shift toward ambulatory, minimally-invasive therapies. Competitive intensity is moderate but rising; patent cliffs on alpha-blockers and 5-ARIs are opening the field for next-generation procedural devices and combo-chemistries, yet payer pressure on urology budgets tempers pricing power.

Long-term, we forecast a 5–6% CAGR through 2032, driven by outpatient laser and implantable technologies that shorten catheter time and reduce readmissions. The innovation pipeline is rich—AI-guided surgical planning, biodegradable urethral stents, and sustained-release injectables are expected to enter pivotal trials within 24 months.

Demand-supply is balanced in mature markets but underserved in emerging Asia, where urologist density lugs prevalence. Key risks include reimbursement tightening, regulatory delays for high-energy devices, and generic erosion of oral segments. Portfolio hedging across device, pharma, and digital health segments is the safest path to sustained share capture.

11 items

1. Executive Summary

2. Benign Prostatic Hyperplasia Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Benign Prostatic Hyperplasia Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Benign Prostatic Hyperplasia Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Centers

6.1.3. Specialty Clinics

6.1.4. Others

6.2. Global Benign Prostatic Hyperplasia Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Drug Class

6.2.2. Minimally Invasive Surgeries

6.2.3. Laser Therapy

6.2.4. Others

6.3. Global Benign Prostatic Hyperplasia Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Benign Prostatic Hyperplasia Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Benign Prostatic Hyperplasia Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Benign Prostatic Hyperplasia Treatment Market Competition by Key Manufacturers

8.1. Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Benign Prostatic Hyperplasia Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Allergan plc

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Astellas Pharma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Asahi Kasei Corporation

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Boehringer Ingelheim GmbH

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GlaxoSmithKline

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Pfizer

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sanofi

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Teva Pharmaceutical Industries

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Merck

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Boston Scientific Corporation

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Teleflex Incorporated

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Endo International

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Urologix

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. LISA Laser

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Olympus

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Benign Prostatic Hyperplasia Treatment Market

Figure 4: Global Benign Prostatic Hyperplasia Treatment Market: Drivers

Figure 5: Global Benign Prostatic Hyperplasia Treatment Market: Challenges

Figure 6: Global Benign Prostatic Hyperplasia Treatment Market: Trends

Figure 7: Global Benign Prostatic Hyperplasia Treatment Market: Opportunity

Figure 8: Global Benign Prostatic Hyperplasia Treatment Market: Restraint

Figure 9: Global Benign Prostatic Hyperplasia Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Benign Prostatic Hyperplasia Treatment Market Value (USD Million) By Region

Figure 15: Global Benign Prostatic Hyperplasia Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Benign Prostatic Hyperplasia Treatment Market Value (USD Million) By Region

Figure 23: Global Benign Prostatic Hyperplasia Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Benign Prostatic Hyperplasia Treatment Market Value (USD Million) By Region

Table 10: Global Benign Prostatic Hyperplasia Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Benign Prostatic Hyperplasia Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Benign Prostatic Hyperplasia Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Benign Prostatic Hyperplasia Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: Allergan plc Basic Information And Sales Area

Table 33: Allergan plc. Products Portfolio

Table 34: Astellas Pharma Basic Information And Sales Area

Table 35: Astellas Pharma. Products Portfolio

Table 36: Asahi Kasei Corporation Basic Information And Sales Area

Table 37: Asahi Kasei Corporation. Products Portfolio

Table 38: Boehringer Ingelheim GmbH Basic Information And Sales Area

Table 39: Boehringer Ingelheim GmbH. Products Portfolio

Table 40: GlaxoSmithKline Basic Information And Sales Area

Table 41: GlaxoSmithKline. Products Portfolio

Table 42: Pfizer Basic Information And Sales Area

Table 43: Pfizer. Products Portfolio

Table 44: Sanofi Basic Information And Sales Area

Table 45: Sanofi. Products Portfolio

Table 46: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 47: Teva Pharmaceutical Industries. Products Portfolio

Table 48: Merck Basic Information And Sales Area

Table 49: Merck. Products Portfolio

Table 50: Boston Scientific Corporation Basic Information And Sales Area

Table 51: Boston Scientific Corporation. Products Portfolio

Table 52: Teleflex Incorporated Basic Information And Sales Area

Table 53: Teleflex Incorporated. Products Portfolio

Table 54: Endo International Basic Information And Sales Area

Table 55: Endo International. Products Portfolio

Table 56: Urologix Basic Information And Sales Area

Table 57: Urologix. Products Portfolio

Table 58: LISA Laser Basic Information And Sales Area

Table 59: LISA Laser. Products Portfolio

Table 60: Olympus Basic Information And Sales Area

Table 61: Olympus. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Benign Prostatic Hyperplasia Treatment Market Value (USD Million) By Region

Table 67: Global Benign Prostatic Hyperplasia Treatment Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current Benign Prostatic Hyperplasia Treatment market size?

Global Benign Prostatic Hyperplasia Treatment market size surpassed USD 11.2 billion in 2023, driven by rising geriatric population and increasing adoption of minimally invasive surgical therapies across major healthcare systems.

2. What is the five-year growth forecast for the BPH treatment sector?

Analysts project a 6.1% CAGR through 2028, propelling the market toward USD 15.1 billion. Growth is underpinned by novel drug launches, expanding reimbursement, and heightened awareness of early surgical intervention options.

3. Which key drivers are accelerating BPH treatment demand?

Aging demographics, increasing prevalence of moderate-to-severe lower urinary tract symptoms, technological shift to laser and robotic procedures, and favorable health-economic data supporting outpatient surgeries are primary demand catalysts.

4. What challenges restrain faster market expansion?

Reimbursement caps for premium devices, post-operative complications leading to readmissions, patient reluctance toward surgical routes, and pricing pressure from generics collectively moderate growth momentum.

5. Which regions lead the Benign Prostatic Hyperplasia Treatment landscape?

North America commands 42% share owing to high procedure volumes and rapid uptake of advanced lasers. Europe follows with strong adoption of combination pharmacotherapy, while Asia-Pacific is the fastest-growing region at 7.3% CAGR.

6. Who are the top companies shaping the competitive arena?

Boston Scientific, Olympus, Karl Storz, UroLift (Teleflex), and Astellas dominate device and pharma segments through portfolio breadth, clinical evidence, and global urology sales networks.

7. What future opportunities offer the highest ROI potential?

Implantable nitinol devices, aquablation systems with AI planning, personalized 5-alpha reductase inhibitor dosing, and telehealth-supported post-procedure monitoring present high-value white spaces for investors.

8. How is technology impacting procedural volumes?

High-powered holmium and thulium lasers reduce catheter time to <24 h, boosting same-day discharge rates above 70%. Robotic-guided enucleation is expanding to ambulatory centers, lifting eligible patient pools by 18%.

9. What does the regulatory landscape look like for new BPH devices?

FDA 510(k) clearances average 8–10 months with robust post-market surveillance requirements; EU MDR mandates clinical evidence updates every two years, influencing trial strategies and labeling claims.

10. How will sustainability shape the future outlook?

Reusable laser fibers, single-use instrument recycling programs, and value-based procurement contracts tied to symptom score improvements are becoming decisive purchasing criteria for hospitals aiming to cut procedural carbon footprints.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Benign Prostatic Hyperplasia Treatment Market Overview

By focusing investigating

Report Overview

Report Attribute	Details
Market size value in 2025	6.90 billion
Revenue forecast in 2033	12.04 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Allergan plc; Astellas Pharma; Asahi Kasei Corporation; Boehringer Ingelheim GmbH; GlaxoSmithKline; Pfizer; Sanofi; Teva Pharmaceutical Industries; Merck; Boston Scientific Corporation; Teleflex Incorporated; Endo International; Urologix; LISA Laser; Olympus
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options